Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2019-04-29 Earnings Release
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2019. It announces the issuance of a press release regarding financial results for the quarter ended March 31, 2019. The text explicitly states that the press release is furnished as an exhibit and is not deemed filed for certain regulatory purposes. The document itself does not contain the financial results but rather announces their release. The length is 3744 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is an announcement of financial results, fitting the category of Earnings Release (ER).
2019-04-29 English
8-K
Audit Report / Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 25, 2019. It announces the dismissal of the former independent registered public accounting firm (PwC) and the engagement of a new independent registered public accounting firm (KPMG). It includes details about the audit reports, disagreements, and reportable events related to the auditors. The document also attaches a letter from PwC to the SEC. This type of filing is specifically about changes in the company's certifying accountant, which falls under announcements related to audit firms rather than the audit report itself or the annual report. Therefore, it fits the category of Audit Report / Information (AR) as it relates to audit firm changes and audit-related disclosures but is not a full audit report or annual report.
2019-04-29 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-17 English
Regulatory Filings 2019
Regulatory Filings
2019-04-11 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 8, 2019. It reports an event where the company received FDA Fast Track Designation for a gene therapy. The document includes a press release as an exhibit. The content is an announcement of a significant event rather than a financial report, earnings release, or management discussion. It is not a full report like an Annual Report or Interim Report, nor is it a transcript or governance document. The 8-K form is used for current reports on material events. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-04-09 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-04-03 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.